• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate.

Scalable Process for High-Yield Production of PfCyRPA Using Insect Cells for Inclusion in a Malaria Virosome-Based Vaccine Candidate.

Details
Files
DOI
10.48350/170507
Publisher DOI
10.3389/fbioe.2022.879078
PubMed ID
35669054
Abstract
Plasmodium falciparum cysteine-rich protective antigen (PfCyRPA) has been identified as a promising blood-stage candidate antigen to include in a broadly cross-reactive malaria vaccine. In the last couple of decades, substantial effort has been committed to the development of scalable cost-effective, robust, and high-yield PfCyRPA production processes. Despite insect cells being a suitable expression system due to their track record for protein production (including vaccine antigens), these are yet to be explored to produce this antigen. In this study, different insect cell lines, culture conditions (baculovirus infection strategy, supplementation schemes, culture temperature modulation), and purification strategies (affinity tags) were explored aiming to develop a scalable, high-yield, and high-quality PfCyRPA for inclusion in a virosome-based malaria vaccine candidate. Supplements with antioxidants improved PfCyRPA volumetric titers by 50% when added at the time of infection. In addition, from three different affinity tags (6x-His, 4x-His, and C-tag) evaluated, the 4x-His affinity tag was the one leading to the highest PfCyRPA purification recovery yields (61%) and production yield (26 mg/L vs. 21 mg/L and 13 mg/L for 6x-His and C-tag, respectively). Noteworthy, PfCyRPA expressed using High Five cells did not show differences in protein quality or stability when compared to its human HEK293 cell counterpart. When formulated in a lipid-based virosome nanoparticle, immunized rabbits developed functional anti-PfCyRPA antibodies that impeded the multiplication of P. falciparum in vitro. This work demonstrates the potential of using IC-BEVS as a qualified platform to produce functional recombinant PfCyRPA protein with the added benefit of being a non-human expression system with short bioprocessing times and high expression levels.
Date Issued
2022-05
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Subjects
BEVS PfCyRPA bioprocess engineering insect cells malaria vaccine
Language(s)
en
Author(s)
Fernandes, Bárbara
Sousa, Marcos
Castro, Rute
Schäfer, Anja
Hauser, Julia
Schulze, Kai
Amacker, Mario  
Universitätsklinik für Pneumologie und Allergologie  
Department for BioMedical Research, Forschungsgruppe Pneumologie (Erwachsene)  
Tamborrini, Marco
Pluschke, Gerd
Alves, Paula M
Fleury, Sylvain
Roldão, António
Additional Credits
Department for BioMedical Research, Forschungsgruppe Pneumologie (Erwachsene)  
Universitätsklinik für Pneumologie und Allergologie  
Journal
Frontiers in Bioengineering and Biotechnology
Publisher
Frontiers Media
ISSN
2296-4185
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify